At a glance
| Reference context | EGF-related cosmetics |
|---|---|
| Identity requirement | Verify sequence, source, and complete formulation |
| Recent human evidence | Small randomized serum comparison |
| Comparator issue | Defined ingredient versus conditioned-media blend |
| Route boundary | Topical cosmetic research |
Overview
The label oligopeptide-1 is used in an EGF-related cosmetic context, including a recent study describing its test serum as recombinant epidermal growth factor. For accurate interpretation, the ingredient specification matters: naming conventions, source, sequence, and manufacturing can differ among products marketed under growth-factor language. A conditioned-media product containing multiple biological components is also different from a defined recombinant ingredient. Products described with similar EGF terminology should therefore not be assumed chemically or clinically equivalent without examining their specifications and direct comparative evidence. The relevant question is what a particular tested serum changed in human skin appearance, and whether the design can identify the responsible ingredient.
How it works
EGF-related research concerns signaling through the epidermal-growth-factor receptor, which influences cellular growth and repair responses. A plausible receptor pathway does not establish that a cosmetic formulation delivers an active molecule through intact skin to the necessary location. Growth-factor signaling also cannot simply be described as universally beneficial. Product identity, exposure, and the specific clinical outcome remain essential to interpreting proposed rejuvenation effects.
A recent randomized pilot
A 2026 blinded pilot randomized twenty women to an oligopeptide-1/recombinant-EGF-context serum or a human-derived conditioned-media serum for twelve weeks. Some investigator-rated texture and firmness outcomes favored the former, while global wrinkle ratings changed little. The small sample and comparison of two multi-component products limit broad conclusions about isolated EGF efficacy.
Supporting sources [1]
What the design cannot establish
The pilot did not compare a purified peptide against an otherwise identical vehicle, and the participants were predominantly White women with a limited range of skin types. It therefore cannot establish equivalent outcomes for all products, skin types, or age groups. A product-level difference is not proof that the named growth factor alone caused it.
Supporting sources [1]
Avoid expanding the claim beyond the study
Cosmetic status is not FDA drug approval. Short-term facial tolerability does not establish long-term effects of growth-factor exposure, application to disrupted skin, or injection. An ingredient listing should not be used to imply approved treatment of ulcers, scars, or other medical conditions without separate product-specific evidence.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Growth-factor-related cosmetic peptide/protein ingredient context.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Synthetic/recombinant-EGF-context versus human-derived growth-factor serum: randomized pilot ↗Clinical trial source · Checked 2026-10-27
- FDA: authority over cosmetics and the distinction from drug approval ↗Regulatory source · Checked 2026-10-27